IL13Rα2 expressed in over 50% of GBM patients (82, 83), which has emerged as one of the most promising CAR-T targets for GBM, promotes tumor progression by inhibiting the STAT6 signaling pathway (84). This evidence concerns the gene STAT6 and glioblastoma.